Document Detail


Doxazosin and congestive heart failure.
MedLine Citation:
PMID:  11691497     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Congestive heart failure (CHF) is the most devastating cardiac sequella of long-standing hypertension. Recent data from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) have shown the risk of CHF to be twice as high with doxazosin than with chlorthalidone. Although some questions remain regarding the diagnosis and mortality of CHF in the doxazosin arm and regarding the risk of dying from malignancy in the diuretic arm of ALLHAT, drugs used to treat hypertension should lower the CHF risk. Therefore, until ironclad safety data are provided, doxazosin, and probably all alpha-blockers, should no longer be used as first-line antihypertensive therapy.
Authors:
F H Messerli
Related Documents :
11297917 - Cardiac malignant lymphoma successfully treated with chemotherapy.
10918647 - Interventional therapy in heart failure management.
2688877 - Ultrafiltration: a rational treatment for heart failure.
7381647 - Doxorubicin cardiotoxicity in children.
6492997 - Mechanisms of methacholine-induced coronary vasospasm in an experimental model of varia...
870947 - In vitro computed tomography of the human heart.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  38     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2001 Nov 
Date Detail:
Created Date:  2001-11-05     Completed Date:  2001-12-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1295-6     Citation Subset:  AIM; IM    
Affiliation:
Department of Internal Medicine, Section on Hypertensive Diseases, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA. fmesserli@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / adverse effects*
Adverse Drug Reaction Reporting Systems
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / adverse effects*
Cause of Death
Diuretics / therapeutic use
Doxazosin / adverse effects*
Drug Therapy, Combination
Heart Failure / chemically induced*,  diagnosis,  epidemiology,  etiology,  prevention & control*
Humans
Hypertension / complications*,  drug therapy*
Morbidity
Neoplasms / chemically induced,  mortality
Patient Selection
Prognosis
Research Design / standards
Risk Factors
Safety
Survival Analysis
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Diuretics; 74191-85-8/Doxazosin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ST segment resolution as a tool for assessing the efficacy of reperfusion therapy.
Next Document:  Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women.